Clinical Trials Directory

Trials / Completed

CompletedNCT03689114

Low vs. Standard Daily Doses of Antiepileptic Drugs in Newly Diagnosed, Previously Untreated Epilepsy(STANDLOW)

Efficacy and Tolerability of Low vs. Standard Daily Doses of Antiepileptic Drugs in Newly Diagnosed, Previously Untreated Epilepsy (STANDLOW). A Multicenter, Randomized, Single-blind, Parallel-group Trial

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
58 (actual)
Sponsor
Mario Negri Institute for Pharmacological Research · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

There are no guidelines on the first maintenance daily dose of antiepileptic drugs (AEDs) in newly diagnosed, previously untreated epilepsy. Original trials and Cochrane reviews show that seizure remission can be achieved with differing daily doses. In clinical practice, the first maintenance dose varies significantly. In contrast, the risk of adverse treatment effects increases with dosage. There is thus the need to identify the lowest effective dose for treatment start. This background prompted us to undertake a randomized multicenter pragmatic non-inferiority trial comparing standard to low daily doses of AEDs to demonstrate that low doses are at least as effective as standard doses (as indicated by the national formulary) but are better tolerated and are associated with a better quality of life. If proven as effective as the standard dose, a low daily dose of AEDs is a benefit to the patient in terms of tolerability and safety and a source of savings for the National Health System.

Conditions

Interventions

TypeNameDescription
DRUGLow dose carbamazepineCarbamazepine, 300 mg/die
DRUGStandard dose carbamazepineCarbamazepine 600 mg/die
DRUGLow dose levetiracetamLevetiracetam 500 mg/die
DRUGStandard dose levetiracetamLevetiracetam 1000 mg/die
DRUGLow dose valproateValproate 300 mg/die
DRUGStandard dose valproateValproate 600 mg/die
DRUGLow dose zonisamideZonisamide 150 mg/die
DRUGStandard dose zonisamideZonisamide 300 mg/die
DRUGLow dose oxcarbazepineOxcarbazepine 600 mg/die
DRUGStandard dose oxcarbazepineOxcarbazepine 1200 mg/die
DRUGLow dose topiramateTopiramate 100 mg/die
DRUGStandard dose topiramateTopiramate 200 mg/die
DRUGLow dose lamotrigineLamotrigine 100 mg/die
DRUGStandard dose lamotrigineLamotrigine 200 mg/die
DRUGLow dose gabapentinGabapentin 450 mg/die
DRUGStandard dose gabapentinGabapentin 900 mg/die

Timeline

Start date
2021-05-10
Primary completion
2024-06-30
Completion
2024-06-30
First posted
2018-09-28
Last updated
2025-07-08
Results posted
2025-07-08

Locations

1 site across 1 country: Italy

Source: ClinicalTrials.gov record NCT03689114. Inclusion in this directory is not an endorsement.